Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
Open Access
- 6 November 2019
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (3) , 417-426
Abstract
Aim: To assess the efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes (T2D). Materials and methods: This multicentre, double‐blind, parallel‐group study randomized Japanese patients with T2D insufficiently controlled with insulin (1:1:1) to empagliflozin 10 mg (n=89), empagliflozin 25 mg (n=90) or placebo (n=90) for 52 weeks. The primary endpoint was change from baseline in glycated haemoglobin (HbA1c) at 16 weeks. Results: At 16 weeks, empagliflozin 10 mg and 25 mg significantly decreased HbA1c: adjusted mean difference −0.92% (95% confidence interval [CI] −1.11, −0.73) and −1.00% (95% CI −1.18, −0.82; both P P P <0.0001). At 52 weeks, the frequency of adverse events (AEs) and serious AEs was similar in the three treatment groups; confirmed hypoglycaemia was reported slightly more in participants in the empagliflozin 10 mg and 25 mg groups (23.3% and 22.2% vs 14.4%). All hypoglycaemic events were mild in severity; no episodes required assistance. Conclusions: In Japanese patients with insufficiently controlled T2D, adding empagliflozin 10 mg or 25 mg to insulin treatment was associated with clinically meaningful reductions in HbA1c at 16 weeks and was generally well tolerated.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 37 references indexed in Scilit:
- Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research DatabaseJournal of Diabetes and its Complications, 2012
- Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)Journal of Diabetes and its Complications, 2012
- Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitorCurrent Medical Research and Opinion, 2012
- Factors influencing initial choice of insulin therapy in a large international non‐interventional study of people with type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism, 2011
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trialsAnnals of Medicine, 2011
- Three-Year Efficacy of Complex Insulin Regimens in Type 2 DiabetesNew England Journal of Medicine, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Insulin Treatment and the Problem of Weight Gain in Type 2 DiabetesThe Diabetes Educator, 2006